Sato Vicki L's Form 4 filing
Denali Therapeutics Inc. (DNLI) · filed Sep 17, 2021
- Accession no.
- 0001714899-21-000091
- Filed
- Sep 17, 2021
- Trade date
- Sep 15, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $89.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sato Vicki LCIK 0001197020 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2021 | Common Stock | SSaleDisposed | −230 | $52.28F2 | −$12,024.4 | 130,935 | Direct | |
| Sep 15, 2021 | Common Stock | SSaleDisposed | −676 | $53.03F4 | −$35,848.28 | 130,259 | Direct | |
| Sep 15, 2021 | Common Stock | SSaleDisposed | −620 | $53.92F5 | −$33,430.4 | 129,639 | Direct | |
| Sep 15, 2021 | Common Stock | SSaleDisposed | −140 | $54.76F6 | −$7,666.4 | 129,499 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $51.56 to $52.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $52.56 to $53.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $53.57 to $54.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F6
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $54.63 to $54.89 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.